Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Open-Label, Single-Arm Study of the Safety and Efficacy of CC-5013 Monotherapy for Subjects With Multiple Myeloma: A Companion Study for Studies THAL-MM-003, CC-5013-MM-009, and CC-5013-MM-010

NCT00622336 is registered in ClinicalTrials.gov with Celgene as lead sponsor.

NCT NCT00622336
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00622336 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Open-Label, Single-Arm Study of the Safety and Efficacy of CC-5013 Monotherapy for Subjects With Multiple Myeloma: A Companion Study for Studies THAL-MM-003, CC-5013-MM-009, and CC-5013-MM-010
Lead sponsor
Celgene
Phase
Phase 3
Overall status
Completed
Start date
April 1, 2003
Completion date
November 25, 2013
Enrollment
330 (actual)
Sites
7

Conditions

As the registry lists them; a condition with its own page is linked.

multiple myeloma